Correction to: Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study (BMC Cancer, (2021), 21, 1, (1207), 10.1186/s12885-021-08881-7)

1Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Following publication of the original article [1], it was identified that due to typesetting mistakes, an unfinalized version of the article were published. The following changes have been implemented. 1) The corresponding author’s email address has been corrected: Phili ppe. Thomp son- Leduc@ analy sisgr oup. com 2) In table 1, note 2, the full reference is: Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863–9. https:// doi. org/ 10. 1200/ JCO. 2015. 61. 2267 3) In table 2, note 3, the full reference is: Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, Lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319–31. https:// doi. org/ 10. 1056/ NEJMo a1607 751 4) In table 3, note 1, the full reference is: Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e46. https:// doi. org/ 10. 1016/ S1470- 2045(16) 30206-6 5) In table 4, note 2, the full reference is: Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e46. https:// doi. org/ 10. 1016/ S1470- 2045(16) 30206-6 6) In the section, Treatment patterns of first daratumumab- based regimen, paragraph three: The text should not have been in bold typeface. 7) In the section, Treatment patterns of first daratumumab- based regimen, paragraph three: “3.3 Clinical outcomes” Was removed from the end of the paragraph. 8) In the abbreviations list, “3 L: Third line or later” was updated to “3 L+: Third line or later” These corrections were typesetting errors and do not influence the results of this article. The publishers apologise for this error. The original article [1] has been updated.

Cite

CITATION STYLE

APA

Atrash, S., Thompson-Leduc, P., Tai, M. H., Kaila, S., Gray, K., Ghelerter, I., … Rossi, A. (2021, December 1). Correction to: Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study (BMC Cancer, (2021), 21, 1, (1207), 10.1186/s12885-021-08881-7). BMC Cancer. BioMed Central Ltd. https://doi.org/10.1186/s12885-021-09015-9

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free